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Abstract
Aim: Evaluate sex differences in procedural net adverse clinical events and long-term
outcomes following rotational atherectomy (RA).
Methods and Results: From August 2010 to 2016, 765 consecutive patients under-
going RA PCI were followed up for a median of 4.7 years. 285 (37%) of subjects were
female. Women were older (mean 76 years vs. 72 years; p < .001) and had more
urgent procedures (64.6 vs. 47.3%; p < .001). Females received fewer radial proce-
dures (75.1 vs. 85.1%; p < .001) and less intravascular imaging guidance (16.8
vs. 25.0%; p = .008). After propensity score adjustment, the primary endpoint of net
adverse cardiac events (net adverse clinical events: all-cause death, myocardial infarc-
tion, stroke, target vessel revascularization plus any procedural complication)
occurred more often in female patients (15.1 vs. 9.0%; adjusted OR 1.81 95% CI
1.04–3.13; p = .037). This was driven by an increased risk of procedural complica-
tions rather than procedural major adverse cardiac events (MACE). Specifically,
women were more likely to experience coronary dissection (4.6 vs. 1.3%; p = .008),
cardiac tamponade (2.1 vs. 0.4%; p = .046) and significant bleeding (BARC ≥2: 5.3
vs. 2.3). Despite this, overall MACE-free survival was similar between males and
females (adjusted HR 1.03; 95% CI 0.80–1.34; p = .81). Procedural complications dur-
ing RA were associated with almost double the incidence of MACE at long-term
follow-up (HR 1.92; 95% CI 1.34–2.77; p < .001).
Abbreviations: ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; CHIP, complex high-risk and indicated patients; CI, confidence intervals; CTO, chronic total occlusion;
IABP, intra-aortic balloon pump; IVUS, intravascular ultrasound; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; NACE, net adverse clinical
events; OA, orbital atherectomy; OR, unadjusted odds ratio; PCI, percutaneous coronary intervention; PEA, pulseless electrical activity; RA, rotational atherectomy; TLR, target lesion
revascularization; TVR, target vessel revascularisation; UFH, unfractionated heparin.
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Conclusion: Women may be at greater risk of procedural complications following
rotational atherectomy. These include periprocedural bleeding episodes and coronary
perforation leading to cardiac tamponade. Despite this, the adjusted overall long-term
survival free of major adverse cardiac events was similar between males and females.
K E YWORD S
calcific coronary disease, complex percutaneous coronary intervention, gender differences,
rotational atherectomy
1 | INTRODUCTION
Cardiovascular disease is the leading cause of death in women.1
Following percutaneous coronary intervention (PCI), women suffer
disproportionately high rates of death,2 bleeding3 and complications
including myocardial infarction (MI) and stroke.4 Furthermore, female
gender is an independent predictor of death, MI, stent thrombosis and
target lesion revascularization after PCI of calcific coronary lesions.5
Rotational atherectomy (RA) may be necessary in calcific coronary
lesions to prevent stent underexpansion or malapposition that are asso-
ciated with higher rates of restenosis or target vessel failure.6 Women
requiring treatment with RA present a unique challenge, often pre-
senting later, with more advanced coronary artery disease, and smaller
caliber peripheral and coronary arteries. Women may be particularly
susceptible to complications following rotational atherectomy (RA) due
to gender-specific differences in arterial access, bleeding and coronary
pathophysiology. This has not been studied in a contemporary cohort,
we therefore designed a study to analyze gender differences in proce-
dural net adverse clinical events (NACE) and assess effects on long-term
outcomes following RA.
2 | METHODS
2.1 | Study population
Over 6 years from August 2010, 16,198 PCIs were analyzed at our high
volume regional center (serving a population of ~2 million). Seven hun-
dred sixty-five consecutive RA procedures were included representing
4.7% of all PCIs performed. Data was obtained from a PCI database
with paired analysis of electronic health records, a nationwide elec-
tronic portal and sourced individual patient case notes. The institutional
review board approved the study and use of patient data.
2.2 | Variables
Baseline characteristics (demographic, clinical, and procedural) were
extracted from our PCI database as entered by the operator. Long-term
follow-up data (minimum 12 months) was obtained through an electronic
health database including nationwide electronic portal with individual
source patient files where needed. Diabetes Mellitus included patients
with diet controlled diabetes and those on treatment according to WHO
criteria. Left ventricular ejection fraction (LVEF) was stratified into three
categories—good (LVEF > 50%), moderately impaired (30–50%), severely
impaired (LVEF < 30%). Arterial access was recorded as radial where the
rotablation procedure was performed exclusively via the radial artery.
This included patients who had a concomitant intra-aortic balloon pump
(IABP) inserted via the femoral artery. Significant renal impairment was
defined as active renal replacement therapy or a serum creatinine
>200 μmoL/L (2.26 mg/dL). Patients with missing data were prospec-
tively recorded in a Appendix S1. Data were assumed to be missing at
random allowing them to be imputed with the use of multivariate impu-
tation by chained equations.
2.3 | Rotational atherectomy procedure
RA was performed using the Boston Scientific Rotablator® system.
Burr speeds were routinely between 150,000 and 170,000 rpm with
smooth back and forth pecking motion performed in runs of up to
20 s duration. Occasionally, further acceleration was used to cross
resistant lesions with a maximum speed of 200,000 rpm. Access site
and sheath size were determined by individual operator preference.
The maximum burr size used and the maximum external sheath size
(which corresponds to arteriotomy size, a more important predictor of
vascular access complications than guiding catheter diameter) were
recorded. In the case of sheathless guiding catheters, the equivalent
maximum external diameter was recorded (e.g., Asahi Sheathless™ 7.5F
guiding catheter has outer diameter of 2.5 mm and is thus considered
<7F arteriotomy). Anticoagulation with intravenous unfractionated hep-
arin (UFH) was used in all cases maintaining an activated clotting time
>250 s. Additional glycoprotein IIb/IIIa antagonists were used in
selected cases at operator discretion.
2.4 | Outcomes
The primary endpoint of this study was the composite incidence of
net adverse clinical events (NACE occurring within 24 hr of PCI). Sec-
ondary endpoints included predictors of NACE events and long-term
survival. NACE was defined as major adverse cardiac events (MACE:
all-cause death, MI, stroke, target vessel revascularization) plus any
procedural complication. Stroke was defined as any focal or global
neurological deficit lasting >24 hr OR < 24 hr with neuroimaging con-
firmation of new hemorrhage or infarct OR the neurological deficit
results in death as per 2012 updated VARC criteria.7 Periprocedural
MI was defined according to the third universal definition.8 Target
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vessel revascularizations (TVR) was defined as any non-staged PCI or
coronary artery bypass grafting (CABG) during the follow-up period.
Procedural complications included coronary artery perforation
leading to cardiac tamponade and major vascular injury according to
the Valve Academic Research Consortium (VARC)9 criteria. Other pro-
cedural complications were coronary dissection, no or slow reflow,
minor access site complication (VARC criteria), significant bleeding
within 24 hr of procedure (Bleeding Academic Research Consortium10
(BARC 2 or greater), arrhythmia (ventricular fibrillation, ventricular
tachycardia, pulseless electrical activity (PEA) cardiac arrest or brady-
cardia requiring temporary pacing line insertion). The occurrence of
procedural complications were identified and verified by an indepen-
dent cardiologist who was not involved in the procedure against the
objective criteria above. The outcomes were evaluated at 30-day,
1-year and longer-term follow-up until August 2018.
2.5 | Statistical analysis
Results are reported as mean (±SD) for parametric data and median
(25th, 75th percentile) for data that was not normally distributed. The
χ2 test (or Fisher's exact test for infrequent events) was used to assess
for differences between categorical variables. Univariate odds ratios
with 95% confidence intervals were calculated to measure strength of
association between categorical variables. One-way ANOVA was used
to assess for differences between means of continuous normally dis-
tributed variables. All multiple comparisons were adjusted using the
Benjamin-Hochberg correction. All analyses were two-tailed analysis
with significance considered as p value <.05 to be significant.
Propensity scores were created for female and male groups and
incorporated to adjust for baseline differences in a multivariable logistic
regression model for procedural NACE. The following variables were
used to calculate the propensity score: Age, procedure urgency/ACS,
previous stroke or myocardial infarction, renal impairment, diabetes
mellitus, hypertension, left ventricular function, previous coronary bypass
grafting, use of intravascular ultrasound for PCI, maximum burr size
≥1.75 mm, maximum arteriotomy (sheath ≥7F), left main lesion location,
number of vessels undergoing HSRA. Covariate balance between groups
was evaluated by the Wald chi-square statistic before and after propen-
sity score adjustment. After adjusting for propensity score, none of the
variables used to create the propensity score were found to be signifi-
cantly different between the male and female groups (Figure 1).
Logistic regression was used to measure the adjusted odds ratio
(OR) and 95% confidence intervals (CI). Multivariate regression models
were used to determine predictors of procedural NACE adjusting for
pre-defined clinically important variables of interest determined by
experienced interventional cardiologists. These included propensity
score adjusted patient factors: age, sex, access site (radial/femoral),
ACS/urgent presentation, renal impairment, left ventricular function,
diabetes mellitus, previous CABG, previous stroke or MI. Procedural
factors included in the model included maximum arteriotomy (sheath)
size, left main lesion location, maximum burr size ≥1.75 mm, use of
intravascular imaging guidance, use of intra-aortic balloon pump, glyco-
protein IIB/IIIA inhibitors. For assessing discrimination of the regression
model, we used the c-statistic corresponding to the area under the
receiver operating characteristic curve (AUC—ROC). An AUC of 0.5
indicates a model with no discrimination value. In cardiovascular risk
prediction models, AUCs are typically in the range of 0.7–0.95. Survival
curves were constructed using cox-regression to assess survival differ-
ences between males and females on MACE-free survival during long-
term clinical follow-up. Statistical analyses were performed with Prism
7.0 (GraphPad, La Jolla, CA) and SPSS 25.0 (SPSS, Chicago, IL).
3 | RESULTS
3.1 | Baseline characteristics
Seven hundred sixty-five consecutive patients undergoing RA were stud-
ied and followed up over a median duration of 4.7 years. There were five
high volume operators (>75 RA procedures: MME, KGO, SW, MML, PR)
who performed 624 (82%) of all RA procedures, and a total of ten main
consultant operators. The mean age of patients was 73 ± 9 years (37%
female). There were no patients unaccounted for at long-term follow-up.
The temporal distribution of HSRA cases over the course of the study is
illustrated in Figure S1. Baseline demographics and procedural details are
shown in Table 1. Women undergoing RA were older (mean 76 ± 8 years
vs. 72 ± 9 years in men; p < .001) with more urgent procedures (64.6
vs. 47.3%; p < .001) and a higher prevalence of hypertension (80 vs. 67%;
p= .002).Women had lower rates of previousCABG, but otherwise similar
baseline demographics factors including anatomical lesion location and
renal function (Table 1). After propensity score adjustment, there were no
differences in the baseline characteristics of patients studied (Figure 1).
3.2 | Procedural characteristics
Radial access was used less frequently in women (75.1 vs. 85.1%,
p < .001, Figure 2A), with the femoral approach therefore significantly
more common (OR 1.91, 95% CI 1.33 to 2.76, p < .001; Figure 2A). Intra-
vascular imaging (IVUS) guidance (16.8 vs. 25%, p = .008) and large burr
sizes (1.75 mm or greater) (30 vs. 40%; p = .018) were used less fre-
quently in women compared with men. Anticoagulation with UFH was
F IGURE 1 Propensity adjustment for baseline differences
between female and male groups [Color figure can be viewed at
wileyonlinelibrary.com]
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used uniformly in all patients. Glycoprotein IIB/IIIA inhibitor use was simi-
lar between the groups (11 vs. 12%; p = .830). The use of temporary
venous pacing upfront was exceptionally low (n = 4; 0.5%) and bailout
use of temporary pacing line was needed in only 6 (0.8%) subjects.
3.3 | Procedural outcomes
After propensity score adjustment, the primary study endpoint (proce-
dural NACE) was over 80% more likely in females than males (15.1
vs. 9.0%; adjusted OR 1.81, 1.04 to 3.13, p = .037; Table 2, Figure 2B).
The differences were driven by procedural complications and not major
adverse cardiac events (adjusted OR complication 2.32; 1.21 to 4.46,
p = .011; Table 2). Specifically, women experienced higher rates of cor-
onary perforation leading to cardiac tamponade (2.1 vs. 0.4%; OR 5.14,
95% CI 1.03 to 25.60) as well as higher rates of iatrogenic coronary
dissection 4.6 vs. 1.3%; OR 3.78,95% CI 1.42 to 10.00). Female gender
was associated with higher rates of periprocedural bleeding (BARC 2 or
greater 5.3 vs. 2.3%; OR 2.37, 95% CI 1.07 to 5.23). Major adverse
cardiac events including procedural MI and stroke rates were not statis-
tically different between the groups.
TABLE 1 Baseline demographics
Female (n = 285) Male (n = 480) p value Adjusted p-valueb
Age (years) 76 (±8) 72 (±9) .001 .993
Acute coronary syndrome/urgent 184 (64.6%) 227 (47.3%) .001 .647
Diabetes 95 (33%) 165 (34%) .190 .985
Hypertension 211 (80%) 300 (67%) .002 .979
Previous cardiovascular event 56 (21%) 106 (23.9%) .716 .980
Previous CABG 23 (8.1%) 76 (16%) .002 .963
Advanced renal diseasea 19 (7.2%) 40 (9.2%) .359 .962
Left ventricular function .939 .996
Good (ejection fraction >50%) 60 (39%) 95 (37%)
Moderate (30–50%) 67 (43%) 114 (44%)
Poor (ejection fraction <30%) 28 (18%) 48 (19%)
Hemoglobin (g/L) 117 (±14) 132 (±18) .001 <.986
Creatinine (μmol/L) 104 (±78) 116 (±94) .099 .616
Procedural characteristics
Radial approach 214 (75%) 409 (85%) .001 .913
Access size ≥7 Frenchc 76 (26.7%) 151 (31.5%) .161 .973
High volume RA operator (>75 cases) 227 (80%) 397 (83%) .291 .404
Intravascular ultrasound guidance 48 (16.8%) 120 (25%) .008 .993
No of vessels treated .184 .998
1 235 (84%) 384 (80%)
2 32 (11%) 74 (16%)
3 14 (5%) 20 (4%)
Maximum burr size (>1.5 mm) 81 (30%) 181 (40%) .018 .951
Lesion location
Left main 82 (28.2%) 127 (27%) .487 .988
Left anterior descending 122 (43%) 237 (49%) .199 .640
Circumflex 48 (17%) 89 (18%) .689 .769
Right 88 (31%) 137 (29%) .237 .524
Bypass graft 1 (0.4%) 2 (0.4%) .888 .995
Glycoprotein 2B/3A use 31 (11%) 59 (12%) .830 .667
Intra-aortic balloon pump 5 (1.8%) 12 (2.5%) .499 .293
Temporary pacing line 1 (0.4%) 3 (0.6%) .611 .996
Notes: Data are mean (SD) and number (%). Significance determined by one-way ANOVA or Pearson-Chi square test for categorical variables.
Abbreviations: CABG, coronary artery bypass grafting; CKD, chronic kidney disease; IABP, intraaortic balloon pump prior to procedure; IVUS, intravascular
ultrasound imaging guidance; TPL, temporary pacing line insertion prior to procedure.
aAdvanced renal disease defined as renal replacement therapy or serum creatinine >200 mmol/L (2.26 mg/dL).
bSheathless guiding catheters are considered by their external diameter and related arteriotomy size (e.g., Asahi Eaucath 7.5F occupies <7F external diameter).
cPropensity score adjusted significance of female versus male groups.
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To assess the goodness of fit and diagnostic accuracy of the
model, we assessed area under the ROC (AUC: Harrell's c-statistic).
The multivariate fitted regression model showed moderate discrimina-
tion potential with an AUC of 0.68 ± 0.03; p < .001 (Figure S2).
3.4 | Predictors of procedural net adverse cardiac
events
The other independent predictors of adverse procedural events during
RA included intervention involving the left main coronary artery
(adjusted OR 1.75; 95% CI 1.01 to 3.04; p = .047), femoral artery
access (adjusted OR 2.06; 1.05 to 4.06; p = .036) with trends towards
increased NACE observed in urgent/ACS procedures and procedures
without intracoronary IVUS imaging (Table 3; Figure 3). Incidence of
NACE was numerically lower in high volume operators however the
differences were not statistically significant (OR 0.81; 0.46 to 1.41;
p = .453). After excluding patients in cardiogenic shock, an exploratory
analysis of interaction between primary femoral arterial access and
femoral access for IABP showed no significant interaction. It should
be noted that the subgroup was small with wide confidence intervals
(OR for NACE with primary femoral 5.74; 0.15–200; p = .343).
3.5 | Clinical events and long-term survival
At thirty days, MACE rates were similar in both groups with 18 (6.3%)
females and 36 (7.5%) males. Long-term major adverse cardiac events
at median 4.7 years follow-up were observed more frequently in
females (47.0 vs. 38.5%; HR 1.25; 1.00–1.56; Figure 4). However after
adjusting for propensity score and baseline factors, the long-term clin-
ical outcomes were similar between groups (HR 1.03; 0.80–1.34;
p = .813; Table 4). There were no differences in the adjusted overall
mortality of patients according to gender at thirty day or longer-term
follow-up. The mortality at 30-days (3.9% females vs. 5.2% males) and
12 months (12.3 vs. 12.7%) was similar between the groups. The
MACE-free survival curves from the unadjusted and adjusted cox
regression models are shown in Figure 4. Procedural complications
F IGURE 2 (A) Gender differences in
RA procedures and (B) net adverse clinical
events (NACE) [Color figure can be
viewed at wileyonlinelibrary.com]
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during RA were independently associated with long-term risk of major
adverse cardiac events (HR 2.03; 1.38 to 2.97; p < .001).
4 | DISCUSSION
In this contemporary cohort of patients undergoing predominantly trans-
radial RA, we showed that female sex is independently associatedwith the
occurrence of procedural net adverse cardiac events (NACE). This was
predominantly driven by an excess of periprocedural bleeding and coro-
nary events, including dissection and perforation leading to tamponade.
Importantly, this effect was seen after propsensity score adjustment and
was not explained by differences in periprocedural anticoagulation strate-
gies or baseline comorbidities. Despite the increase in complications,
female gender was not independently associated with short term or long-
term mortality after RA. However this study did show that procedural
NACE were prognostically important and independently associated with
reduced long-term survival after RA PCI.
4.1 | Rotational atherectomy procedural
complications: Females at high risk
Our study provides real-world evidence of the risk/treatment paradox
in women undergoing complex PCI with RA. Women are at greatest
risk of complications but are under-served in the best practices known
to reduce risk (e.g., less radial approach, less intravascular imaging
guidance). A recent MATRIX sub-study confirmed that women have a
higher risk of severe bleeding and access site complications in the set-
ting of ACS. Radial access was an effective method to reduce these
complications, as well as impacting on the composite ischemic, and
ischemic or bleeding endpoints.11
A large contemporary UK cohort study confirmed that radial
access was used less often for RA in women versus men (31.6
vs. 37.1%; p < .001) with both of these rates being approximately half
the rate of radial access in our centre.12 Radial access for complex
procedures including RA is increasing which may help reduce compli-
cations in this high risk cohort.13 While larger studies provide power
to assess hard binary endpoints such as mortality, it is plausible that
TABLE 2 Procedural Net Adverse Clinical Events
Gender Unadjusted Adjustedd
Female (n = 285) Male (n = 480) OR (95% CI) p Value OR (95% CI) p-Value
Net adverse clinical events (NACE) 42 (15%) 42 (9%) 1.80 (1.14 − 2.84) 0.010 1.81 (1.04 − 3.13) 0.037
MACE 10 (4%) 24 (5%) 0.70 (0.35 − 1.42) 0.333 0.71 (0.29 − 1.73) 0.455
Complication 36 (13%) 29 (6%) 2.24 (1.35 − 3.76) 0.002 2.32 (1.21 − 4.46) 0.011
MACE components:
Death 3 (1%) 13 (3%) 0.38 (0.11 − 1.35) 0.122
Stroke 3 (1%) 1 (0.2%) 5.10 (0.53 − 49.22) 0.117
Myocardial infarction 4 (1%) 10 (2%) 0.67 (0.21 − 2.15) 0.587
TVR 1 (0.4%) 1 (0.2%) 1.69 (0.11 − 27.07) 0.709
Complications:
Major Vascular Injurya 2 (1%) 0 (0%) 8.47 (0.41 − 177.15) 0.066
Tamponade (Perforation) 6 (2%) 2 (0.4%) 5.14 (1.03 − 25.64) 0.026
Any Coronary Perforationb 12 (4%) 10 (2%) 2.07 (0.88 − 4.85) 0.089
Coronary Dissection 13 (5%) 6 (1%) 3.78 (1.42 − 10.05) 0.004
No Reflow/Slow Flow 1 (0.4%) 4 (0.8%) 0.42 (0.05 − 3.77) 0.423
Bleed (BARC 2 or greater)c 15 (5%) 11 (2%) 2.37 (1.07 − 5.23) 0.028
Minor Vascular Injurya 4 (1%) 4 (1%) 1.69 (0.42 − 6.83) 0.454
Arrhythmia
Arrest: VF/VT/PEA 3 (1%) 6 (1%) 0.84 (0.21 − 3.39) 0.807
Bradycardia (TPL) 1 (0%) 5 (1%) 0.33 (0.04 − 2.88) 0.295
Other 2 (1%) 3 (1%) 1.12 (0.19 − 6.77) 0.902
All events independently adjudicated and occurring within 24 hours of procedure. NACE was defined as major adverse cardiac events (MACE: all-cause
death, MI, stroke, target vessel revascularization) plus any prespecified procedural complication. Periprocedural MI: Type IV myocardial infarction
according to the third universal definition. Bradycardia (TPL): Severe bradycardia requiring insertion of temporary pacing line. OR: odds ratio. TVR: target
vessel revascularization. Significance determined by Pearson-Chi square test.
aVascular injury defined according to Valve Academic Research Consortium (VARC) minor and major criteria.
bCoronary perforation (Ellis classification 1-5).
cBleeding Academic Research Consortium (BARC) criteria. Other complications include contrast allergy and stent dislodgement requiring retrieval.
dAdjustment incorporating propensity score only performed for NACE events, small sample bias precludes adjustment for MACE individual components.
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our study (including detailed independent review of individual case files
and source documents) had enhanced ability to detect periprocedural
complications including coronary artery dissection, periprocedural
bleeding and type IV myocardial infarction. These important complica-
tions may vary by gender and could be overlooked in large registries.
The overall coronary artery perforation rate in our complex patient
cohort was 2.9%. In addition to device perforations, this included wire
perforations or minor contained perforations thought to relate more
to the coronary calcification and post dilation than the atherectomy
itself.14 Perforations in other cohorts have been reported as “device
perforations” rather than “any perforation” and are reported in up to
2.5% of RA15–17 and 1.9% of orbital atherectomy procedures.18
Whether female gender is independently predictive of PCI compli-
cations is controversial and varies according to the population stud-
ied.19 Large studies show no overall difference in mortality after
adjustment for age and other baseline differences between men and
women undergoing PCI.20 Nevertheless, gender differences may
become more apparent in complex high-risk and indicated patients
(CHIP) where procedural risks are substantially greater. Indeed, there
is significant overlap between our cohort with complex co-morbidities
and calcific disease and the chronic total occlusion (CTO) PCI popula-
tion. A large contemporary CTO registry similarly showed that women
suffer more periprocedural complications including coronary perfora-
tion and bleeding (women 10.0 vs. men 4.5%, p = .0012).21
4.2 | Clinical translation: Mechanisms and
implications for clinicians
Radial access was used in this study of RA PCI in three quarters of
women, however, even higher uptake could help to close the gender
gap in periprocedural complications—particularly vascular access com-
plications and bleeding. Increased awareness of the greater risk for
RA in women should help focus CHIP operators in their efforts to
minimize these risks. Selection of the radial approach can be facili-
tated by sheathless guiding catheters to facilitate selective coronary
engagement in women with small caliber radial arteries. The high rates
of coronary perforation highlight the importance of judicious balloon
sizing in women and the value of intravascular imaging to accurately
size and assess calcified lesions and PCI outcomes. Interestingly, the
use of IVUS guidance was significantly lower in women than men in
our cohort, which may partly explain differences in perforation rates
between the groups. The reason for this difference is not clear but
was not explained by gender differences in target lesion location. It is
possible that operators are less inclined to use intravascular imaging in
small reference diameter vessels instead choosing to use the technol-
ogy to confirm stent sizing and apposition in larger vessels. Interest-
ingly, large burrs were used less frequently in women but we did not
find large burr sizes to be a multivariate predictor of RA complications
F IGURE 3 Multivariate predictors of net adverse clinical events
[Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Predictors of procedural net
adverse clinical events
Unadjusted Adjusted
OR 95% CI p value OR 95% CI p value
Left main 1.65 1.02 2.64 .040 1.75 1.01 3.04 .047
Femoral 2.07 1.28 3.36 .003 2.06 1.05 4.06 .036
Female 1.80 1.14 2.84 .011 1.81 1.04 3.13 .037
ACS/urgent 2.16 1.33 3.50 .002 1.85 0.92 3.70 .084
Large burra 1.37 0.90 2.16 .130 1.22 0.66 2.27 .517
No IVUS 1.78 0.94 3.37 .075 2.10 0.99 4.45 .054
Notes: Univariate categorical comparison using odd's ratio, 95% CI. Multivariate regression incorporating
prespecified variables of interest: age, gender, access site, renal function, creatinine, hemoglobin,
previous coronary bypass surgery, previous stroke or MI, diabetes mellitus, maximum external sheath
size, left ventricular function, left main lesion, procedure urgency, maximum burr size, and intravascular
ultrasound use (IVUS).
Abbreviations: ACS, acute coronary syndrome; OR, odds ratio.
aUse of burr ≥1.75 mm during procedure. Regression model fit (AUC 0.68 ± 0.03; p < .001).
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after adjusting for other variables including sheath/guiding catheter
size. Use of less aggressive burr sizes may reduce short-term compli-
cations, however, larger sizes are sometimes necessary for adequate
calcium modification to prevent stent underexpansion.
This study raises the important question—why are women dif-
ferent? Certainly smaller coronary and peripheral arteries may be
more prone to perforation and dissection. Female gender and older
age are significant risk factors for bleeding after PCI.22 Calcific cor-
onary disease in women may differ in etiology, detection, and may
present later for PCI. There is well documented interplay between
osteoporosis, vascular calcification, and cardiovascular events. Cal-
cium supplements may increase cardiovascular events,23 and with
women more prone to osteoporosis, early or prolonged treatment
for this may predispose them to vascular complications related to
calcification.
4.3 | Limitations
This study represents the largest contemporary cohort of majority
transradial RA PCI, involving the use of newer techniques and drug
eluting stents, with long-term follow-up. Our hypothesis was
prespecified and mechanistically plausible, however the data was ana-
lyzed retrospectively which could introduce bias. Our regional center
admits patients from 14 referring hospitals covering a population of
2.5 million, so with all RA PCI performed in a single high-volume cen-
ter our findings may not be generalizable. We adjusted for differences
in baseline and clinical characteristics, however the possibility of
unmeasured confounding variables remains. For examples, female
patients may have had higher periprocedural blood pressure which
was not entered as a baseline variable and could have driven the
excess of periprocedural bleeding. As with all cross-sectional observa-
tional studies, our study does not prove causation from the observed
association. Body weight and surface area was not available and is
known to affect bleeding risk which may explain some of the differ-
ences between males and females in our study. Missing data was lim-
ited and dealt with in a standard fashion, however this can reduce the
power of the study to detect associations. We used gross meaures of
angiographic disease type (lesion location, number of vessels treated)
however more detailed angiographic parameters were not recorded
(e.g., vessel tortuosity, calcification, lesion length).
TABLE 4 Long-term clinical outcomes after rotational atherectomy according to sex (propensity adjusted hazard ratios)
Gender Unadjusted Adjusted*
Female (n = 285) Male (n = 480) HR (95% CI) p value HR (95% CI) p-value
Long-term MACE 134 (47.0%) 185 (38.5%) 1.25 (1.00–1.56) .051 1.03 (0.80–1.34) .813
Death 116 (40.8%) 157 (32.9%) 1.30 (1.02–1.66) .032 1.00 (0.75–1.32) .995
Myocardial infarction 17 (6.0%) 20 (4.2%) 1.35 (0.70–2.61) .369 1.40 (0.64–3.08) .401
Stroke 10 (3.5%) 7 (1.5%) 2.17 (0.81–5.81) .125 1.90 (0.56–6.49) .303
TVR 3 (1.1%) 16 (3.3%) 0.56 (0.15–2.07) .383 1.20 (0.26–5.53) .611
Notes: Unadjusted cox regression and *propensity score adjusted cox regression. Female sex was not associated with long-term mortality after propensity
adjustment including covariables: age, acute coronary syndrome presentation, left ventricular dysfunction, hemoglobin, renal impairment, access site,
previous CABG, diabetes mellitus, procedural net adverse clinical events. Patients who suffered procedural deaths (<24 hr) were excluded from the model.
At median follow-up of 4.7 years, there were 317 (41%) MACE—includes all-cause mortality, nonfatal myocardial infarction, stroke/TIA, target vessel
revascularization. There were 272 (36%) deaths, 36 (5%) nonfatal myocardial infarctions, and 12 (2%) target vessel revascularization.
Abbreviations: MACE, major adverse cardiac events; TVR, target vessel revascularisation.
F IGURE 4 Long-term MACE free survival after RA (stratified by gender). MACE, major adverse cardiac events; RA, rotational atherectomy
[Color figure can be viewed at wileyonlinelibrary.com]
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4.4 | Future research
Our study highlights that females may be at higher risk of RA compli-
cations and requires further evaluation in high risk PCI data sets. Alter-
native strategies for treating calcific coronary disease are evolving
however data from randomized trials is lacking. Intravascular lithotripsy
holds promise and may reduce complications including bleeding by
facilitating smaller guiding catheters and sheath sizes.24 Nevertheless,
RA facilitates PCI of balloon uncrossable lesions which remain the achil-
les' heel of other plaque modification and atheroablative devices. Addi-
tionally, a new iteration of the Rotablator® device is being released
(RotaPro®) which represents the first major development of a main-
stream RA device in decades.
5 | CONCLUSIONS
Women may be at greater risk of net adverse cardiac events (NACE)
after rotational atherectomy. These risks include periprocedural bleed-
ing episodes and coronary perforation leading to cardiac tamponade.
The adjusted overall long-term survival is not different between males
and females. Efforts to close the gender gap in NACE should be
focused on strategies to reduce bleeding, enhancing best practice
transradial PCI incorporating accurate vessel sizing to avoid coronary
perforations.
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